Abstract
Introduction
Hemangiomas are benign vascular tumors that are common in childhood. If located around the orbit, it may cause amblyopia and permanent vision defects. Therefore, early treatment is very important. Our aim in this study is to assess the treatment outcomes and clinical characteristics of patients with periocular hemangioma.
Materials and Methods
Cases with periocular hemangioma who applied to the clinic between 2013 and 2023 were included in this study. The data of the cases were examined from hospital records. Propranolol treatment was used in patients at a dose of 1-2 mg/kg/day. During the follow-up, blood sugar, heart rate and blood pressure were monitored. Treatment responses of the patients were obtained from the hemangioma photo archive.
Results
Of the 55 patients included in the study, 67.3% (n = 37) were female and 32.7% (n = 18) were male. Their average age was 6.7 months (1-36). There was a history of premature birth in 25.5% (n=14) of the cases. Three cases were diagnosed with PHACE syndrome. According to the location, the most common hemangioma was in the upper eyelid in 45.5% (n=25) of the cases, and the second most frequent was in the lower eyelid in 32.7% (n=18). Oral propranolol was started in 87.2% (n=48), topical timolol maleate treatment was started in 5.5% (n=3), and oral glucocorticoid and propranolol treatment was started in 3.6% (n=2). The average treatment duration of the patients was 12.8 (±9.8) months. In the evaluation made according to treatment response, a complete or almost complete response to treatment was obtained in 60% (n = 33) of the cases, and a partial response was obtained in 25.5% (n=14) of the cases. Amblyopia developed in 9.1% (n=5) cases. At the last follow-up, visual impairment was observed in two cases.
Conclusion
Amblyopia still poses a great risk if the patient is not followed well. It may cause permanent vision loss. Propranolol treatment provides great benefits. However, due to its side effects, it should be started in experienced centers.
Keywords: Hemangioma, propranolol, amblyopia
References
Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth WA. Vascular anomalies (Part I): classification and diagnostics of vascular anomalies. Rofo. 2018;190:825-35.
Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012;161:240-5.
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? a systematic review of the medical literature. Pediatr Dermatol. 2008;25:168-73.
Smithson SL, Rademaker M, Adams S, Bade S, Bekhor P, Davidson S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 2017;58:155-9.
Hoeger PH, Harper JI, Baselga E, Bonnet D, Boon LM, Ciofi Degli Atti M, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174:855-65.
Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012;130:e314-20.
Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122:360-7.
George A, Mani V, Noufal A. Update on the classification of hemangioma. J Oral Maxillofac Pathol. 2014;18:117-20.
Spence-Shishido AA, Good WV, Baselga E, Frieden IJ. Hemangiomas and the eye. Clin Dermatol. 2015;33:170-82.
Jung HL. Update on infantile hemangioma. Clin Exp Pediatr. 2021;64:559-72.
· TM, Ceisler E, Broude C, Chan K, Pacicco L, Fay A, et al. Distribution and clinical characteristics of periorbital infantile hemangiomas. Facial Plast Surg Aesthet Med. 2023;25:172-8.
Aletaha M, Salour H, Bagheri A, Raffati N, Amouhashemi N. Oral propranolol for treatment of pediatric capillary hemangiomas. J Ophthalmic Vis Res. 2012;7:130-3.
Krowchuk DP, Frieden IJ, Mancini AJ, Darrow DH, Blei F, Greene AK, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143:e20183475.
Joseph J, Wain T. Infantile haemangiomas: identifying high-risk lesions in primary care. Aust J Gen Pract. 2021;50:887-92.
Alniemi ST, Griepentrog GJ, Diehl N, Mohney BG. Incidence and clinical characteristics of periocular infantile hemangiomas. Arch Ophthalmol. 2012;130:889-93.
Samuelov L, Kinori M, Rychlik K, Konanur M, Chamlin SL, Rahmani B, Mancini AJ. Risk factors for ocular complications in periocular infantile hemangiomas. Pediatr Dermatol. 2018;35:458-62.
Tavakoli M, Yadegari S, Mosallaei M, Aletaha M, Salour H, Lee WW. Infantile periocular hemangioma. J Ophthalmic Vis Res. 2017;12:205-11.
Menapace D, Mitkov M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol. 2016;46:1494-506.
Haggstrom AN, Garzon MC, Baselga E, Chamlin SL, Frieden IJ, Holland K, et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics. 2010;126:418-26.
Frank RC, Cowan BJ, Harrop AR, Astle WF, McPhalen DF. Visual development in infants: visual complications of periocular haemangiomas. J Plast Reconstr Aesthet Surg. 2010;63:1-8.
Jamshidian-Tehrani M, Nabavi A, Taghavi M, Sharif-Kashani S, Kasaee A, Sadeghi-Tari A, et al. Clinical and ultrasonographic evaluation of infantile periocular hemangioma treated with oral propranolol. Ophthalmic Plast Reconstr Surg. 2019;35:484-6.
Porubanova M, Sharashidze A, Hornova J, Gerinec A. β-blockers in the treatment of periocular infantile capillary haemangioma. Neoplasma. 2015;62:974-9.
Ginguerra MA, Saito O, Fernandes JBVD, Castro DS, Matayoshi S. Clinical and radiological evaluation of periocular infantile hemangioma treated with oral propranolol: a case series. Am J Ophthalmol. 2018;185:48-55.
Gomulka J, Siegel DH, Drolet BA. Dramatic shift in the infantile hemangioma treatment paradigm at a single institution. Pediatr Dermatol. 2013;30:751-2.
Chu DH, Castelo-Soccio L, Wan J, Gelfand JM, Shaddy RE, Shah KN, et al. Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). Clin Pediatr (Phila). 2014;53:1084-90.
Haik BG, Jakobiec FA, Ellsworth RM, Jones IS. Capillary hemangioma of the lids and orbit: an analysis of the clinical features and therapeutic results in 101 cases. Ophthalmology. 1979;86:760-92.
Bejjanki KM, Akhtar K, Gupta AP, Kaliki S. Effect of oral propranolol on periocular infantile capillary hemangioma: outcomes based on extent of involvement. Middle East Afr J Ophthalmol. 2021;28:6-10.
Fabian ID, Ben-Zion I, Samuel C, Spierer A. Reduction in astigmatism using propranolol as first-line therapy for periocular capillary hemangioma. Am J Ophthalmol. 2011;151:53-8.
